Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.45 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.44 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064432 | 0.94 | GAA (0.49) | GAAMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL3066509 | 0.90 | GAA (0.51) | GAAMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL3059637 | 0.90 | GAA (0.51) | GAAMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL3063119 | 0.88 | GAA (0.58) | GAAMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL3067529 | 0.85 | GAA (0.49) | GAAMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL3059166 | 0.83 | STAT3 (0.58) | — | |
| SCHEMBL10181168 | 0.83 | STAT3 (0.63) | — | |
| SCHEMBL3052983 | 0.82 | STAT3 (0.57) | — | |
| SCHEMBL3061602 | 0.82 | RAB9A (0.50) | GAAMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL10180761 | 0.82 | STAT3 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | GAA 4287/4885MAPT 4138/4885MAPK1 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.